Posted by Michael Wonder on 02 Jun 2023
First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use
2 June 2023 - NICE’s final draft guidance recommends mavacamten (Camzyos, Bristol-Myers Squibb) as an add-on to standard care that aims to control symptoms of the disease.
Clinical trial evidence suggests that mavacamten and standard care is more effective than standard care alone, and that it may avoid or postpone the need for invasive surgery.
